Cook Medical’s Zilver PTX Trial shows sustained patency after 3 years
Structural Heart
Post-CoreValve pacemaker use may be on the decline
One in 4 patients who received Medtronic’s (NYSE:MDT) CoreValve system between Dec. 2007 and March 2012 also received a pacemaker to counter complications following the procedure, but that’s down from earlier reports and new strategies may push rates even lower.
TAVI: Boston Scientific enrolls 1st patient in Reprise II Lotus valve study
Boston Scientific (NYSE:BSX) enrolled the 1st patient in a new trial of its Lotus transcatheter aortic valve system, expecting to use the results to support a bid for European CE Mark and other international regulatory approvals.
The new study, Reprise II, will ultimately involve up to 120 patients at 15 centers in Australia, France, Germany and the U.K, according to a company statement.
Heart valves: Edwards Lifesciences, Medtronic to face stiffer competition
It’s not your father’s transcatheter aortic valve implant anymore.
Next year and the year after, the competitive landscape for TAVI will explode, with as many as 12 competing devices on the market here and across the pond.
And that competition will be fierce. As TAVI celebrates its 10th birthday,at least 1 analyst is predicting a 20%+ compound annual growth rate for the market, which she says could potentially double by 2015.
Edwards Lifesciences loses 19% on lower Q3 outlook
The European debt crisis, a delayed reimbursement decision and summer vacations conspired to reduce expected 3rd-quarter sales for Edwards Lifesciences (NYSE:EW), sending its share price plunging on Wall Street.
Direct aortic approach feasible for Medtronic’s CoreValve heart implant
TAVI pioneers celebrate 10 years and more than 50,000 patients treated
The 1st transcatheter aortic valve was implanted 10 years ago, laying the foundation for a game-changing technology that has since matured "from an ugly duckling into a beautiful swan," according one researcher.
New valves for babies that can grow with them
By Tom Ulrich
TAVI global registry delivers 1st results | MassDevice.com On Call
Updated October 3, 2012, at 9:45 p.m. to correct the lead story.
MASSDEVICE ON CALL — The 1st reports from a global registry evaluating Edwards Lifesciences’ (NYSE:EW) Sapien transcatheter aortic valve implantation inside a failing valve or mitral ring came with mixed results.*
Medtronic confirms launch of diabetic-friendly Resolute Integrity stent in India
Medical device maker Medtronic (NYSE:MDT) confirmed market launch in India for its Resolute Integrity drug-eluting stent system for heart disease patients with diabetes.
The Resolute Integrity DES was the 1st device of its kind approved for use in patients with diabetes in addition to coronary artery disease, which makes up about ⅓ of all those with CAD.
Medtronic lands EU win for smallest CoreValve replacement heart valve
Medical device heavyweight Medtronic (NYSE:MDT) won CE Mark approval in the European Union for a new size of its CoreValve Evolut transcatheter aortic valve implants, the company announced.
The new 23 mm valve, the smallest in the CoreValve suite, allows Medtronic to provide the "broadest range of TAVI patient valve sizes," according to a press release.